Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals (Nasdaq: SCPH) announced two abstracts from the FREEDOM-HF study will be presented at the AAHFN Annual Meeting in Orlando on June 15-18. The study's primary results indicate that patients treated with FUROSCIX incurred nearly $18,000 less in 30-day heart failure-related costs compared to traditional inpatient care. The New Drug Application for FUROSCIX is under review, with a Prescription Drug User Fee Act date set for October 8, 2022. The company is gearing up for a potential Q4 2022 commercial launch if approved.

scPharmaceuticals Inc. (Nasdaq: SCPH) has announced that CEO John Tucker will present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM EDT in New York City. The presentation will focus on the company's mission to develop and commercialize products aimed at optimizing therapies and reducing healthcare costs. A live webcast will be available on their website under the Investor Relations section. Headquartered in Burlington, MA, scPharmaceuticals specializes in outpatient treatments for acute conditions, particularly in heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH), a company dedicated to innovative healthcare solutions, announced its CEO John Tucker will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 3:00 PM EDT in Miami, FL. The conference aims to highlight advancements in outpatient care and healthcare cost reduction. A live webcast of the presentation will be available on the company's Investor Relations webpage. scPharmaceuticals specializes in developing products for outpatient care, focusing on IV-strength treatments for heart failure and infectious diseases.

scPharmaceuticals reported a net loss of $7.7 million for Q1 2022, compared to $7.1 million in Q1 2021. Cash, cash equivalents, and investments totaled $65.6 million, down from $75.5 million at the end of 2021, but sufficient to fund operations into 2023. The FDA set a PDUFA action date for FUROSCIX at October 8, 2022, with a potential commercial launch in Q4 2022 if approved. The company is ramping up commercial readiness, including finalizing pricing research and distribution partnerships.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that the FDA has accepted its New Drug Application for FUROSCIX, a formulation of furosemide delivered via an on-body infusor, targeting treatment for heart failure-related congestion. The FDA set a PDUFA action date for October 8, 2022. CEO John Tucker highlighted that FUROSCIX addresses a critical healthcare need and may lead to significant cost savings. The company is preparing for a potential Q4 2022 commercial launch contingent on FDA approval.

scPharmaceuticals (Nasdaq: SCPH) has resubmitted its New Drug Application (NDA) for FUROSCIX, aimed at treating decompensated heart failure. The FDA review is anticipated to conclude by Q4 2022, contingent on approval. The company reported that West Pharmaceutical Services has also completed development of related support documentation. CEO John Tucker highlighted the importance of this milestone and noted the promising cost-saving data from the FREEDOM-HF study, suggesting potential market success if approved.

scPharmaceuticals Inc. (SCPH) has completed all testing for FUROSCIX and plans to re-submit its New Drug Application (NDA) by April 15, 2022, aiming for a Q4 2022 commercial launch. The company ended Q4 2021 with $75.5 million in cash and investments, down from $105.3 million in 2020. It reported a net loss of $7.3 million for Q4 2021, slightly better than the $7.8 million loss in Q4 2020. R&D expenses increased to $4.5 million, while G&A expenses decreased to $2.2 million. The company forecasts a net loss of $43 to $48 million for 2022.

BURLINGTON, Mass., Feb. 16, 2022 – scPharmaceuticals (Nasdaq: SCPH) announced that John Tucker, CEO, will present at the 42nd Annual Cowen Healthcare Conference on March 8 at 1:30 PM EST. The company focuses on optimizing therapies and reducing healthcare costs through innovative products, particularly in outpatient care for heart failure and infectious diseases. A live webcast of the presentation will be available on the company's website. For more information about scPharmaceuticals, visit www.scpharmaceuticals.com.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 4:20pm EDT. The presentation aims to highlight the company's innovative approach to developing products that reduce healthcare costs and improve patient care. scPharmaceuticals focuses on outpatient care for acute conditions, particularly in heart failure and infectious diseases. A live webcast will be available on their investor relations website.